Nvidia Q2 FY27: $96.2B Beat, Guides Q3 to $108B ±2%
Nvidia posted $96.2B in Q2 FY27 revenue — a $5B beat on its own guide — with data center at $89B, EPS at $2.46 and Q3 set at $108B.
stock market
Intuit -9%: FY27 Guide Slows, Mailchimp Split Out
Intuit beat Q4 with revenue up 14% to $4.4B, but FY27 guidance of 9-10% growth, a 2-3% TurboTax outlook, and a Mailchimp segment carve-out sank INTU.
DKS -31%: DICK’S Comps +4.9%, Foot Locker -3.6%
Dick’s Sporting Goods stock plunged 30.7% after Q2 FY26 as Foot Locker proforma comps fell 3.6% and management cut the full-year operating income outlook.
Quantum Stocks Rip: RGTI +11%, IONQ +8%, QBTS +8%, QUBT +10%
Quantum computing names surged Friday as IonQ, Rigetti, D-Wave and Quantum Computing Inc. all posted 8-11% gains on Q2 results and fresh analyst calls.
Nvidia Q2 FY27 Preview: $91B Guide, 3 Numbers That Matter
Nvidia reports Q2 FY27 after the close on Wed. Aug 26. The guide is $91B revenue at 74.9% GAAP margin. Here are the three prints traders will trade.
Bitcoin Rips to $77K: MSTR +8%, COIN +8%, MARA +16%
Bitcoin jumped 7.3% to $77,128, pulling crypto-linked equities along for a bigger ride: MSTR +7.8%, COIN +7.6%, MARA +15.5%, HUT +8.0%. CLARITY Act is the catalyst.
Advance Auto -24%: EPS Beat, Guide Raised, DIY Cracked
Advance Auto Parts crashed 24.55% on August 20 even after beating on EPS and raising 2026 guidance. Here’s what actually broke — and what it means for the consumer trade.
Walmart Beats and Raises but WMT Falls 9.7% to 52-Week Low
Walmart topped estimates and raised FY27 guidance, yet WMT fell 9.74% to $103.17. Soft US comps, a tariff-refund-funded raise, flat Q3 EPS, and higher capex explain why.
Target Q2: EPS $4.11, Comps +3.8%, Turnaround Traction
Target Q2 2026 earnings: EPS $4.11 (up 20% ex-tariff refund), comps +3.8%, digital +8.7%, guidance lifted. Stock +4.3% as turnaround gains traction.
Moderna +177%, Merck +13% on Melanoma Vaccine Phase 3 Win
Moderna soared 177% and Merck jumped 13% on Aug 19 after intismeran plus Keytruda hit its primary endpoint in the Phase 3 INTerpath-001 melanoma trial.